Intertek expands pharmaceutical services capacity with acquisition of new facility in Melbourn, Cambridge
10 Dec 2025
Further elevating expert development support for next generation inhaled medicines
Melbourn, UK: Intertek, a leading Total Quality Assurance provider to industries worldwide, is significantly expanding its Good Manufacturing Practice (GMP) pharmaceutical services with the acquisition of an additional 29,000 square feet facility in Melbourn, near Cambridge, UK.
This expansion responds directly to the rapid growth of innovative drug development programmes and rising client demand for expert support in the inhaled biologics space. The new facility will empower Intertek to conduct multiple clinical trial material manufacturing campaigns simultaneously while maintaining the flexibility and agility needed to support each client’s evolving development needs.
Adjacent to Intertek’s current facilities, the new building will significantly expand current manufacturing and laboratory space to enhance capabilities for inhaled and nasal drug development. The initial development phase of the new facility is scheduled to open in the second quarter of 2026, with additional expansions planned from 2026 to 2028.
On opening, the facility will feature an expanded manufacturing suite containing three additional production rooms offering increased efficiency and output. It will also elevate Intertek’s capabilities to develop both solid and liquid inhaled formulations, focusing on next-generation dry powder biopharmaceuticals and a variety of other innovative drug delivery formats. Furthermore, dedicated laboratory spaces will be established for comprehensive analytical testing, particle engineering, device selection, characterisation and performance testing, reinforcing the company’s commitment to supporting the evolving needs of the biopharmaceutical industry.
Teresa Iley, Director – Pharmaceutical Development & Manufacturing at Intertek, commented: “The landscape of inhaled and nasal drug development is evolving rapidly, demanding novel analytical techniques, innovative formulation technologies and integrated device solutions. Our new facility gives innovators the flexibility and technical resources to explore these frontiers, supporting everything from method development to clinical trial materials production in one collaborative environment.”
Ross McCluskey, Executive Vice President, Europe, Middle East and Africa and Government and Trade Services at Intertek, said: “This strategic expansion underscores Intertek’s commitment to providing robust analytical methods and scalable GMP clinical manufacturing, ensuring that clients can transition their novel technologies from proof of concept to late-stage clinical trials.”
For over 30 years, Intertek’s Melbourn facility has specialised in providing analytical, formulation and clinical manufacturing services to help clients from the pharmaceutical, biotechnology and drug delivery industries to meet key milestones for their challenging pharmaceutical development programmes through systemic, end-to-end Total Quality Assurance solutions.
For Media Information:
Please contact:
Lorna Kettle
ECA Marketing Director, Intertek Pharmaceutical Services
T: +44 (0) 116 296 1620
E: lorna.kettle@intertek.com
About Intertek
TOTAL QUALITY. ASSURED.
Intertek is a leading Total Quality Assurance provider to industries worldwide.
Our network of more than 1,000 laboratories and offices in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers' operations and supply chains.
Intertek is a purpose-led company to Bring Quality, Safety and Sustainability to Life. We provide 24/7 mission-critical quality assurance solutions to our clients to ensure that they can operate with well-functioning supply chains in each of their operations.
Our Customer Promise is: Intertek Total Quality Assurance expertise, delivered consistently, with precision, pace and passion, enabling our customers to power ahead safely.
intertek.com
About Intertek Pharmaceutical Services
Intertek’s pharmaceutical services locations include Melbourn, Cambridge (UK), Manchester (UK), Basel (Switzerland), Whitehouse, (New Jersey, USA), Mumbai (India) and Melbourne, (Australia).
Intertek’s scientists continue to lead the way in pharmaceutical testing with this increased capacity for innovative drug development support. By partnering with us, pharmaceutical companies can ensure compliance, mitigate risks, and maintain the highest standards of product quality and safety.
Intertek.com/pharmaceutical
